Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

personalised Diabetes Management using lOw-cost Needle-free multiple-biomarkers monitoring Device

Objectif

"""Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of “diabetes self-management” and the most effective solution to reduce the economic and societal burden of diabetes. But the shortcomings of current CGMs hinder their wider adoption: high cost, unsatisfactory predictability of severe events, and poor user comfort. The DiaMOND project will remove these barriers by bringing needle-free, low-cost Continuous Diabetes Monitoring to market. DiaMOND is specifically geared at extending Indigo’s current CGM with reliable severe clinical event prediction and a great user experience; demonstrating the reliability in a first-in-man trial; creating market acceptance by involving Key Opinion Leaders; and obtaining reimbursement. Indigo will be ready for a large pivotal clinical study and CE marking after completing the DiaMOND project. DiaMOND will accelerate Indigo’s CDM market access by 2-3 years."""

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

SME-2 - SME instrument phase 2

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) H2020-EIC-SMEInst-2018-2020

Voir tous les projets financés au titre de cet appel

Coordinateur

INDIGO DIABETES
Contribution nette de l'UE
€ 2 493 273,13
Adresse
BOLLEBERGEN 2B/30
9052 Gent
Belgique
PME
Oui
Région
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 4 519 408,75